Global Regorafenib
Market Report
2025
Regorafenib Market size is USD 1558.5 million in 2024 and will expand at a compound annual growth rate (CAGR) of 11.00% from 2024 to 2031.
The base year for the calculation is 2024. The historical will be 2021 to 2024. The year 2025 will be estimated one while the forecasted data will be from year 2025 to 2033. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Regorafenib Market Report 2025.
According to Cognitive Market Research, the global Regorafenib market size is USD 1558.5 million in 2024 and will expand at a compound annual growth rate (CAGR) of 11.00% from 2024 to 2031.
2021 | 2025 | 2033 | CAGR | |
---|---|---|---|---|
Global Regorafenib Market Sales Revenue | 121212 | 121212 | 121212 | 11% |
North America Regorafenib Market Sales Revenue | 121212 | 121212 | 121212 | 9.2% |
Europe Regorafenib Market Sales Revenue | 121212 | 121212 | 121212 | 9.5% |
Asia Pacific Regorafenib Market Sales Revenue | 121212 | 121212 | 121212 | 13% |
South America Regorafenib Market Sales Revenue | 121212 | 121212 | 121212 | 10.4% |
Middle East Regorafenib Market Sales Revenue | 121212 | 121212 | 121212 | 10.7% |
Base Year | 2024 |
Historical Data Time Period | 2021-2024 |
Forecast Period | 2025-2033 |
Market Split by Dosage |
|
Market Split by Application |
|
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Report scope is customizable as we have a huge database of Regorafenib industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Regorafenib Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Regorafenib, a well-known kinase inhibitor in the pharmaceutical industry, has garnered widespread recognition for its efficacy in treating advanced cancers. Marketed under various brand names, this targeted therapy has proven its worth in the oncology market, inhibiting multiple enzymes involved in angiogenesis and tumor growth. Its approval for indications like advanced gastrointestinal stromal tumors and metastatic colorectal cancer has fueled its market expansion. The Regorafenib market encompasses its manufacture, sale, and usage, which stakeholders closely monitor for their impact on clinical outcomes and quality of life. Factors such as research advancements, regulatory approvals, and evolving treatment paradigms in oncology influence market dynamics. Continuous clinical trials exploring Regorafenib's potential in diverse cancer types further contribute to its evolving landscape.
Another significant driver of the Regorafenib market is the increasing focus on personalized medicine. With advancements in biomarker testing and molecular profiling, Regorafenib's efficacy can be better matched to individual patient characteristics, optimizing treatment outcomes. This emphasis on tailored therapies enhances demand for Regorafenib and underscores its importance in the evolving landscape of oncology care. .
In March 2024, Amgen revealed fresh findings from the Phase 3 SPROUT trial, presenting 52-week results. The study investigates the application of Otezla® (apremilast) in pediatric patients aged 6 to 17 with moderate to severe plaque psoriasis.
One key driver in the Regorafenib market is the changing treatment paradigms in oncology. Changing treatment paradigms in oncology, marked by innovations like targeted therapies, immunotherapy, and precision medicine, drive global demand. Tailored approaches optimize efficacy while minimizing side effects, revolutionizing cancer care. Combining therapies, such as chemotherapy with immunotherapy, enhances treatment outcomes. Liquid biopsies for early detection and monitoring further elevate the demand for advanced diagnostics. Embracing value-based care ensures cost-effective treatments, expanding access to cutting-edge therapies. These transformative shifts in oncology treatment paradigms promise more effective, personalized, and accessible cancer treatments, underpinning increased global demand.
Another key driver in the Regorafenib market is the generic competition and cost-effectiveness considerations. With patents expiring, generic versions offer lower-cost alternatives, enhancing affordability and patient access. Healthcare systems prioritize cost-effectiveness, weighing Regorafenib's clinical benefits against its expense and alternatives. Comparative effectiveness research and health economic evaluations inform decisions, evaluating efficacy, safety, and overall value. Generic competition fosters price reductions, supporting budget-conscious healthcare systems and patients. Striking a balance between cost and clinical outcomes ensures sustainable access to Regorafenib therapy. Through embracing generic competition and cost-effectiveness considerations, stakeholders aim to optimize patient care while managing healthcare expenditures effectively.
One key restraint in the Regorafenib market is the high treatment cost. The substantial expense associated with Regorafenib therapy can limit patient access and strain healthcare budgets, particularly in regions with limited resources. High treatment costs may deter patients from seeking or adhering to treatment, impacting overall treatment efficacy and outcomes. Additionally, healthcare providers may face challenges in justifying the cost of Regorafenib compared to alternative therapies or standard treatments. Addressing the issue of high treatment costs requires strategies to improve affordability, such as pricing negotiations, reimbursement support, and the development of cost-effective treatment regimens. Without measures to mitigate the financial burden, the growth potential of the Regorafenib market may be hampered.
The COVID-19 pandemic has had a multifaceted impact on the Regorafenib market. On the one hand, disruptions in healthcare services, including delays in cancer screenings, diagnoses, and treatments, have led to decreased demand for cancer therapies, including Regorafenib. Additionally, supply chain disruptions and logistical challenges have affected the availability of Regorafenib and other medications, potentially leading to shortages and interruptions in treatment. On the other hand, the pandemic has underscored the importance of telemedicine and remote monitoring, facilitating continuity of care for patients receiving Regorafenib. Moreover, research efforts to understand the interaction between COVID-19 and cancer treatments, including Regorafenib, have accelerated, potentially leading to new insights and treatment strategies. Overall, the COVID-19 pandemic has presented both challenges and opportunities for the Regorafenib market, reshaping dynamics in cancer care delivery and research.
We have various report editions of Regorafenib Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.
The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.
Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.
Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.
Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.
The competitive landscape of the Regorafenib market includes key pharmaceutical companies such as Bayer AG, Amgen Inc., and Teva Pharmaceutical Industries Ltd., among others, vying for market share through product innovation, strategic collaborations, and geographic expansion. Generic competition and regulatory approvals shape market dynamics, with companies focusing on enhancing the affordability, accessibility, and efficacy of Regorafenib for various cancer indications
Top Companies Market Share in Regorafenib Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. North America emerges as the dominant region in the Regorafenib market due to several key factors. These include an increasing incidence of cancer, particularly colorectal cancer and hepatocellular Carcinoma, for which Regorafenib is indicated. Further, advancements in precision medicine and targeted therapies have expanded the application of Regorafenib in various cancer types. The introduction of generic versions of Regorafenib also contributes to market expansion by enhancing affordability and accessibility. Overall, these factors collectively drive the growth of the North American market for Regorafenib.
Asia-Pacific stands out as the fastest-growing region in the Regorafenib market due to several compelling reasons. Rising cancer prevalence, particularly colorectal cancer, and hepatocellular Carcinoma fuels demand for Regorafenib, approved for these indications. Moreover, improving healthcare infrastructure, increasing awareness of advanced cancer treatments, and expanding access to innovative therapies contribute to market expansion. Additionally, regulatory approvals and advancements in precision medicine drive the adoption of Regorafenib across the region. Furthermore, strategic collaborations between pharmaceutical companies and healthcare providers facilitate market penetration. Overall, these factors, coupled with the growing burden of cancer in the APAC region, drive the growth of the Regorafenib market
The current report Scope analyzes Regorafenib Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
According to Cognitive Market Research, the global Regorafenib market size was estimated at USD 1558.5 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 623.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031. In North America, the Regorafenib market exhibits a promising landscape characterized by increasing incidences of colorectal cancer and hepatocellular Carcinoma, coupled with advancements in precision medicine. Regional analysis reveals that the United States and Canada are the primary contributors to market growth, driven by factors such as favorable reimbursement policies and expanding healthcare infrastructure. Segmentation analysis further highlights the popularity of 40 mg dosage in the region, catering to effective therapy for patients with metastatic colorectal cancer and other indications. Its accessibility and established efficacy contribute to its prominence, providing clinicians with a well-established treatment option. In conclusion, North America presents a lucrative market opportunity for Regorafenib manufacturers, driven by expanding indications, personalized medicine approaches, and increasing adoption of targeted therapies.
According to Cognitive Market Research, the global Regorafenib market size was estimated at USD 1558.5 Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD 467.55 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.5% from 2024 to 2031. In Europe, the Regorafenib market presents a dynamic landscape characterized by increasing adoption of targeted therapies and precision medicine approaches. Regional analysis indicates that countries like Germany, the UK, and France are the key contributors to market growth, driven by factors such as expanding approvals for various cancer indications, including colorectal cancer and hepatocellular Carcinoma. Segmentation analysis further highlights the increasing incidences and prevalence in the region, with Colorectal Cancer being the dominant category. This segment reflects a critical component of the oncology landscape in Europe, where Regorafenib plays a pivotal role in addressing the therapeutic needs of patients. In conclusion, Europe represents a lucrative market for Regorafenib manufacturers, driven by expanding indications, personalized medicine initiatives, and increasing adoption of targeted therapies.
According to Cognitive Market Research, the global Regorafenib market size was estimated at USD 1558.5 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 358.46 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.0% from 2024 to 2031. In the Asia Pacific region, the Regorafenib market exhibits robust growth prospects driven by increasing healthcare infrastructure and expanding access to innovative treatments. Regional analysis indicates that countries such as China, Japan, South Korea, and India are key contributors to market expansion, with regulatory approvals and strategic collaborations facilitating penetration. Hepatocellular Carcinoma segmentation analysis shows the importance of this segment for Regorafenib. Its approval and utilization as a treatment option for advanced HCC contribute to its prominence in the oncology landscape, addressing the therapeutic needs of patients and offering opportunities for improved outcomes in this challenging indication. In conclusion, the Asia Pacific region presents immense growth opportunities for Regorafenib manufacturers, fueled by regulatory approvals, strategic partnerships, and investment in research and development.
According to Cognitive Market Research, the global Regorafenib market size was estimated at USD 1558.5 Million, out of which Latin America market of more than 5% of the global revenue with a market size of USD 77.93 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2031. In Latin America, the Regorafenib market showcases promising growth prospects driven by factors such as rising cancer incidence rates, particularly in colorectal cancer and hepatocellular Carcinoma. Regional analysis indicates that countries like Brazil, Mexico, Argentina, and Chile are significant contributors to market growth. Increasing access to innovative treatments, regulatory approvals, and strategic collaborations further fuel market expansion across the region. Colorectal cancer segmentation analysis reveals a diverse range of applications for Regorafenib in Latin America, driven by increasing incidence rates and the need for effective treatment options. In conclusion, Latin America presents significant growth opportunities for Regorafenib manufacturers, driven by the increasing adoption of precision medicine approaches and investment in research and development.
According to Cognitive Market Research, the global Regorafenib market size was estimated at USD 1558.5 Million, out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 31.17 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.7% from 2024 to 2031. MEA, the Regorafenib market, showcases promising growth prospects driven by factors such as Expanding indications, increasing access to innovative treatments, and improving healthcare infrastructure. Regulatory approvals and strategic collaborations further enhance market potential. 80 mg dose plays a crucial role in delivering effective therapy for patients with advanced malignancies. Its accessibility and established efficacy contribute to its prominence, providing clinicians with a valuable treatment option in the management of cancer. In conclusion, MEA presents significant growth opportunities for Regorafenib manufacturers, driven by rising cancer prevalence, increasing adoption of precision medicine approaches, and opportunities for pharmaceutical companies to address unmet medical needs.
Global Regorafenib Market Report 2025 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Regorafenib Industry growth. Regorafenib market has been segmented with the help of its Dosage, Application , and others. Regorafenib market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
According to Cognitive Market Research, 40 mg stands out as the dominating category. While the standard starting dose is 160 mg, lower doses may be prescribed for patients with specific needs or those experiencing intolerable side effects. This segment's growth is fueled by increasing recognition of personalized medicine, where dosage adjustments optimize treatment outcomes while minimizing adverse effects. Additionally, ongoing research and clinical trials exploring the efficacy of lower doses contribute to heightened interest and adoption. As healthcare providers tailor treatments to individual patient needs, the demand for a 40 mg dosage of Regorafenib continues to expand, driving segment growth.
80 mg emerges as the fastest-growing category in the Regorafenib market. As clinicians strive to balance efficacy and tolerability, the 80 mg dosage provides a crucial midpoint between the standard 160 mg dose and lower doses for patients with reduced tolerance. This dosage adjustment allows for better management of adverse effects while maintaining therapeutic benefits. Moreover, emerging clinical data and real-world evidence supporting the effectiveness of the 80 mg dose contribute to its increasing adoption. As healthcare providers seek optimized treatment regimens, the 80 mg segment of Regorafenib stands out as the fastest-growing, meeting the demand for tailored therapy approaches.
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Regorafenib Industry. Request a Free Sample PDF!
According to Cognitive Market Research, the dominating category is colorectal cancer (CRC). Its prevalence and the approval of Regorafenib as a treatment option post-progression on standard therapies have solidified its position. Widely used for metastatic CRC, Regorafenib addresses a critical need in this indication, contributing significantly to its market share. With CRC being one of the most common cancers globally, the demand for effective therapies like Regorafenib remains high. As a result, CRC continues to drive the market for Regorafenib, underscoring its importance in the treatment landscape for this prevalent and challenging malignancy.
The fastest-growing category in the Regorafenib market is hepatocellular Carcinoma. With rising global incidence rates and the approval of Regorafenib for HCC treatment in certain regions, its market share in this indication is rapidly expanding. HCC, a primary liver cancer, poses a significant health burden worldwide, particularly in regions with high rates of chronic liver disease. Regorafenib's efficacy in HCC offers a promising therapeutic option where few effective treatments exist, driving its accelerated adoption. As awareness increases and regulatory approvals extend, HCC is poised to become a key growth driver for Regorafenib, shaping its market trajectory.
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Senior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Disclaimer:
Dosage | 40 mg, 80 mg, 120 mg |
Application | Colorectal Cancer, Gastrointestinal Stromal Tumors, Hepatocellular Carcinoma, Others |
List of Competitors | Bayer AG (Germany), Amgen Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Novartis International AG (Switzerland), Pfizer Inc. (United States), Merck & Co., Inc. (United States), AstraZeneca PLC (United Kingdom), Roche Holding AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Bristol Myers Squibb (United States), Beacon Pharmaceuticals, Drug International, Bayer Pharmaceuticals |
This chapter will help you gain GLOBAL Market Analysis of Regorafenib. Further deep in this chapter, you will be able to review Global Regorafenib Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
This chapter will help you gain North America Market Analysis of Regorafenib. Further deep in this chapter, you will be able to review North America Regorafenib Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
This chapter will help you gain Europe Market Analysis of Regorafenib. Further deep in this chapter, you will be able to review Europe Regorafenib Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
This chapter will help you gain Asia Pacific Market Analysis of Regorafenib. Further deep in this chapter, you will be able to review Asia Pacific Regorafenib Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
This chapter will help you gain South America Market Analysis of Regorafenib. Further deep in this chapter, you will be able to review South America Regorafenib Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
This chapter will help you gain Middle East Market Analysis of Regorafenib. Further deep in this chapter, you will be able to review Middle East Regorafenib Market Split by various segments and Country Split.
Chapter 6 Middle East Market Analysis
This chapter will help you gain Middle East Market Analysis of Regorafenib. Further deep in this chapter, you will be able to review Middle East Regorafenib Market Split by various segments and Country Split.
Chapter 7 Africa Market Analysis
This chapter provides an in-depth analysis of the market share among key competitors of Regorafenib. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Dosage Analysis 2019 -2031, will provide market size split by Dosage. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Dosage Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Application Analysis 2021 - 2033
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Regorafenib market
Chapter 12 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Chapter 13 Research Methodology and Sources
Why 40 mg have a significant impact on Regorafenib market? |
What are the key factors affecting the 40 mg and 80 mg of Regorafenib Market? |
What is the CAGR/Growth Rate of Colorectal Cancer during the forecast period? |
By type, which segment accounted for largest share of the global Regorafenib Market? |
Which region is expected to dominate the global Regorafenib Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|